Drug development in this area, including study of the potentially promising chemopreventative benefits of COX-2 inhibitors in cancer, was dramatically halted in 2005 with the world-wide withdrawal of rofecoxib and the continued controversy surrounding the cardiovascular safety issues of these drugs. The gene discussed is PTGS2; the disease is cancer.